Back

Empagliflozin inhibits increased Na influx in HFpEF cardiomyocytes and reduces arrhythmic activity in human atrial trabeculae

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Young Investigator Awards Session in Basic Science Heart Failure ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Maximilian Trum

University Hospital Regensburg, Regensburg (Germany)

3 More presentations in this session

Presentation thumbnail
Aberrant interaction between TEAD1 and Lamin A/C causes cardiomyopathy
Doctor S. Yamada (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Atrial-specific reduction of Kir2.1 channel pore diameter in addition to loss of inward-going rectification underlies inducible atrial fibrillation in a mouse model of short QT syndrome type 3
Miss A. Moreno Manuel (Rehovot, IL)
Abstract Slides Video
Presentation thumbnail
Single-cell transcriptomics reveals an angiogenic cell population for therapeutic angiogenesis in adipose tissue
Doctor O. Inoue (Kanazawa, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Awards Session in Basic Science

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Combined class I and class III antiarrhythmic effects of sotagliflozin - insights from heterologous expressions systems and atrial cardiomyocytes
thumbnail
Congress Presentation
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients
thumbnail
Congress Presentation
Inflamed atrial tissues of patients with atrial fibrillation are characterized by pro-oxidant and pro-remodeling responses: synergistic inhibition by an SGLT2 inhibitor plus a GLP-1R activation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources